Financial Data and Key Metrics Changes - Revenue for Q4 2025 was approximately $4.1 million, up from $3.9 million in the prior year, indicating strong performance across the business [11] - Full year revenue was approximately $12.8 million, down from $13.9 million in 2024, primarily due to the strategic exit from low-margin floral and lettuce segments [15] - Gross profit for Q4 was approximately a $1.2 million loss compared to flat in 2024, reflecting deliberate investments to secure shelf space for 2026 [13] - Full year gross profit was approximately a loss of $0.2 million compared to a gain of $2.3 million in 2024, with a focus on recovering gross margins in 2026 [15] Business Line Data and Key Metrics Changes - Strong performance in cut herbs and the vitamin and supplement portfolio, with double-digit growth driven by new retail placements [7] - Significant growth in the condiment platform, supported by new customer wins such as Wakefern and Safeway [7] - The nutraceutical business showed strong growth in the double-digit range year-over-year, expected to be a larger component of revenue growth going into 2026 [24] Market Data and Key Metrics Changes - The global ready-to-drink (RTD) category is estimated at approximately $842.5 billion in 2025 and projected to reach roughly $1.26 trillion by 2033, representing a significant market opportunity [9] - The company is expanding its retail footprint to nearly 6,000 store locations, reflecting growing demand for its products and strong retail relationships [6] Company Strategy and Development Direction - The company is evolving from a core controlled environment agricultural platform to a broader innovation-driven consumer packaged goods business, focusing on higher growth and higher margin opportunities [6] - Key next steps include expanding into the RTD category, leveraging existing infrastructure and retail relationships to meet growing demand [8] - The company aims to scale its presence in higher margin RTD shelf-stable categories while continuing to diversify its consumer packaged goods business beyond fresh produce [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver predictable and scalable results as it transitions to a more vertically integrated, innovation-driven model [10] - The company is focused on managing costs while investing in infrastructure to support a higher margin, more scalable business model [16] - Management is optimistic about the growth trajectory, citing strong demand for fresh goods and the potential of the RTD market [42] Other Important Information - The company made deliberate investments in onboarding new retail customers during a seasonally compressed period, expecting cost structures to normalize as programs mature [12] - Selling, general, and administrative expenses increased to approximately $15.3 million in 2025, driven by the Natural Shrimp acquisition and other capital market activities [16] Q&A Session Summary Question: How should margins be viewed as the business transitions from fresh to CPG products? - Management expects more robust margins in the RTD and consumer packaged goods segments due to their shelf-stable nature, which reduces shrink issues associated with fresh products [20][22] Question: What is the expected revenue breakdown for CPG versus fresh through 2026? - The core controlled environment agriculture (CEA) business is expected to return to steady growth in the high single digits, while the RTD business presents significant revenue opportunities with margins in the 20%-30% range [24] Question: What products will be offered in the RTD category? - The company plans to focus on protein segment products, including private label offerings for major retailers, leveraging existing relationships to drive sales [26][30] Question: What are the CapEx requirements and timeline for the Midwest facility? - While specific numbers were not disclosed, management indicated that significant capital expenditures will be needed for equipment and facility retrofitting, with plans to be in the marketplace by late 2027 [35]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was approximately $4.1 million, up from $3.9 million in the prior year, indicating strong business performance [10] - Full year revenue was approximately $12.8 million, down from $13.9 million in 2024, primarily due to the strategic exit from low-margin floral and lettuce segments [12] - Gross profit for Q4 was approximately a $1.2 million loss compared to flat in 2024, reflecting elevated costs from onboarding new retail customers [11] - Full year gross profit was approximately a loss of $0.2 million compared to a gain of $2.3 million in 2024, with a focus on recovering gross margins in 2026 [13] - Selling, general, and administrative expenses for the full year were approximately $15.3 million, up from $11.6 million in 2024, driven by the Natural Shrimp acquisition and other capital market activities [14] Business Line Data and Key Metrics Changes - Strong performance in core produce and consumer packaged goods (CPG) categories, with double-digit growth in cut herbs and continued strength in the vitamin and supplement portfolio [6] - Significant growth in the condiment platform, supported by new customer wins such as Wakefern and Safeway [6] - Incremental distribution of over 700 additional retail locations, expanding reach across key markets [6] Market Data and Key Metrics Changes - The global ready-to-drink (RTD) category is estimated at approximately $842.5 billion in 2025 and projected to reach roughly $1.26 trillion by 2033, representing a significant market opportunity [8] Company Strategy and Development Direction - The company is evolving from a core controlled environment agricultural platform to a broader innovation-driven CPG business, focusing on higher growth and higher margin opportunities [5] - Plans to expand into the RTD category, leveraging existing infrastructure and retail relationships to meet growing demand for clean label, shelf-stable nutrition [7] - The strategy includes scaling presence in higher margin RTD categories while diversifying the CPG business beyond fresh produce [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue gaining market share and expanding distribution, supported by strong retail relationships [5] - The focus remains on executing the strategy to deliver predictable and scalable results, positioning the company for sustainable long-term growth [9] - Management highlighted the importance of maintaining strong relationships with existing customers to drive future growth [41] Other Important Information - The company is developing a state-of-the-art RTD manufacturing initiative at its Midwest facility, with plans to meet growing retailer demand at scale [8] - The investment in new accounts during Q4 is seen as necessary to secure shelf space and deepen relationships with major retailers [11] Q&A Session Summary Question: How should we view the margins from fresh to CPG products? - Management expects more robust margins from the RTD and CPG business due to the stability of shelf-stable products compared to fresh goods [16][17] Question: What is the expected revenue breakdown for CPG versus fresh through 2026? - The core CEA business is expected to return to steady growth, while the nutraceutical business showed strong growth, with RTD business anticipated to have significant revenue opportunities and higher margins [23][24] Question: Where specifically will the RTD products be positioned? - The RTD products will primarily be in the protein segment, with plans to develop private label products for major retailers [26][27] Question: What are the CapEx requirements and timeline for the Midwest facility? - The facility will require significant CapEx for machines and retrofitting, with plans to be in the marketplace by the end of 2027 [35]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $5.6 million, down from $7.7 million in 2024, primarily due to the timing of customer equipment purchases [13] - Gross margin improved to approximately 55%, up from 46% in 2024, reflecting lower cost of sales and a reduction in inventory reserves [13] - Total operating expenses decreased by approximately 10% to $6.9 million from 2024 [14] - The net loss improved to $3.7 million or $0.19 per share, compared to a net loss of $4.5 million or $0.22 per share in 2024 [14] Business Line Data and Key Metrics Changes - The backlog of orders for support services increased by 16%, and BIT Solution orders rose by 24% in Q1 2026 compared to the same period last year, indicating a growing recurring revenue trajectory [10][16] - The SteraMist Integrated System achieved its first commercial installation at a leading CDMO in June 2025, with four fully operational installations by year-end [4] - A signed purchase contract of $500,000 was secured in December 2025 for integration into sterile manufacturing [5] Market Data and Key Metrics Changes - The FDA's late 2025 approval of hydrogen peroxide as a direct food additive is a significant regulatory moment, leading to engagements with major partners like Danone and Nestlé [8] - The global ethylene oxide market was valued at $5.29 billion last year, with rising demand for sterilized medical consumables driving growth [11] Company Strategy and Development Direction - The company is focusing on execution and converting its pipeline into recognized revenue while advancing its technology platform [12] - A shift towards a recurring revenue model is emphasized, moving from episodic revenue to embedded revenue, which is expected to enhance customer dependency on the company's solutions [32][33] - The company is prioritizing open bid solution orders and annual service offerings to drive additional revenue and deeper product adoption [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was a challenging year but expressed optimism about the future, highlighting operational momentum and a growing customer base [4][11] - The management noted that customers are beginning to move forward with deferred capital expenditure projects, indicating signs of improvement in the economic environment [58] Other Important Information - The company received approvals from the HSE and BPR submissions, enhancing its recognition in the UK and the Netherlands [10] - The company is preparing to introduce its IHP device to the U.S. market through the FDA 510(k) pre-market notification process [11] Q&A Session Summary Question: Insights into global opportunities mentioned in the quarter - Management expects many EU states to follow suit with registrations, leveraging existing relationships and distributors [41] Question: Thoughts on operating expenses going forward - Operating expenses are expected to slightly decrease as a percentage of revenue growth, with leverage already in place [43] Question: Signs of improvement in customer CapEx projects - Management confirmed that they are seeing customers who deferred projects beginning to move forward [58] Question: Details on BIT Solution revenues for 2025 versus 2024 - There was an increase in BIT Solution usage, with customers moving towards auto shipment and advanced orders [62] Question: Potential military applications for SteraMist - Management acknowledged the idea and indicated they would explore opportunities with the military, particularly in light of recent health concerns [75]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $87.2 million, aligning with the midpoint of revised guidance, while full-year revenue reached $346.8 million, a 1.4% increase over 2024 [3][4] - Adjusted EBITDA for Q4 was $19.2 million, representing a margin expansion to 22%, up from 20.4% in Q4 2024, while full-year Adjusted EBITDA was $68.7 million, a 23% year-over-year increase [4][19] - Free cash flow for the year was $20 million, an increase of $5 million over 2024, with cash flow from operations rising to $37 million, a 19% increase year-over-year [4][15] Business Line Data and Key Metrics Changes - Financial Health revenue totaled $56.2 million in Q4, a 2% year-over-year increase, while Patient Care revenue was $31 million, reflecting a 6.6% decline primarily due to the sunset of the Centriq product [18][19] - Bookings for Q4 were $19.8 million, up $6 million year-over-year, supported by growing SaaS and strategic partnerships, with total bookings for the year at $82.9 million, a 1% increase [4][20] Market Data and Key Metrics Changes - The overall sales pipeline value is at its highest in nine quarters, increasing by 53% since the beginning of Q3, with a notable shift towards larger opportunities and recurring deals [5][6] - The percentage of recurring deals in the pipeline has improved to over 70%, up from approximately 57% last summer, indicating a healthier demand environment [5] Company Strategy and Development Direction - The company is engaged in a strategic review process to maximize shareholder value and is not issuing formal guidance, but expects modest revenue growth in 2026 and a 200 basis points improvement in Adjusted EBITDA margins [3][22] - A focus on AI strategy spans financial health, patient care, customer service, and internal development, with initiatives aimed at improving claims processing and customer interactions [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in customer retention, particularly in the CBO segment, and has implemented a structured transition model to improve retention rates [6][7] - The company is optimistic about the operational changes and believes it is on the right trajectory for future improvements, despite potential delays in consistent quarterly performance [6][11] Other Important Information - The company has strengthened its financial position through disciplined debt reduction, lowering net debt by approximately $19.5 million year-to-date, and improving its net leverage ratio to 2x [15][16] - The company opened a new Global Capacity Center in Chennai, marking a significant milestone in its global delivery model [8] Q&A Session Summary Question: Can you explain the visibility on revenue growth in relation to new bookings? - Management confirmed that recurring revenues and assumptions of bookings at conversion are key to understanding revenue visibility [25][26] Question: How is customer retention improving in the CBO segment? - Management indicated that retention rates are not yet at desired levels but are showing modest improvement, with a focus on ensuring smooth transitions for customers [27][28] Question: What is the timeline for the strategic review process? - Management stated there is no set timeline for the strategic review, emphasizing the importance of achieving the right outcome over meeting deadlines [30] Question: How should we think about the conversion timing of larger deals in the pipeline? - Management noted that there are no capacity constraints, but the timing of bookings is often dependent on customer readiness [34][35] Question: What synergies exist between Patient Care and Financial Health? - Management highlighted the interconnectivity between the two segments, particularly in serving rural community customers and expanding technology offerings [43][44] Question: What impact will the Rural Health Fund have on customer bases? - Management is actively engaging with hospitals to help them access the $50 billion fund, viewing it as a significant opportunity [70][72] Question: How is AI being leveraged in the business? - Management is cautious about AI implementation, focusing on projects that provide clear ROI and improve customer experience [76][77]

Financial Data and Key Metrics Changes - KULR Technology Group recorded a net loss of approximately $62 million in 2025, primarily driven by one-time and non-cash items [4] - Revenue for 2025 was $16.1 million, representing a 51% increase from the previous year, with growth largely attributed to Bitcoin mining and battery research grant dollars [8][28] - Battery platform revenue, which includes product sales and contract services, was $7.3 million in 2025, serving as the baseline for scaling in 2026 [8] Business Line Data and Key Metrics Changes - Product revenue increased by 39% in 2025, while service revenue declined by 50% [28] - The gross margin for product sales was reported at 1% in 2025, reflecting the challenges of early-stage manufacturing [9] - KULR has over 30 active customer development programs across various platforms, including KULR ONE Air, KULR ONE Space, and KULR ONE Guardian [12][18] Market Data and Key Metrics Changes - The KULR ONE Air platform is experiencing the most momentum, with over 20 active customer development agreements and a target of 10,000 battery packs per month by late 2026 [29][35] - KULR has entered a five-year preferred battery supply agreement with Caban Energy, which is expected to contribute to revenue growth in the telecom sector [22][33] Company Strategy and Development Direction - The company's mission for 2026 is to eliminate distractions and focus on building and selling more KULR ONE batteries [6] - KULR aims to improve gross margins through automation and increased production volume, with an automated production line set to be installed in the second half of 2026 [10] - The company is strategically focused on high-growth markets such as autonomous platforms, digital infrastructure, and direct energy systems, which require specialized battery solutions [11][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in 2025 but emphasizes a strong foundation for growth in 2026, focusing on core battery revenue growth and improvements in gross margin [5][11] - The demand for high-power battery packs is identified as a significant growth driver, particularly in specialized applications that require performance and reliability [11][19] - Management expresses confidence in the stability and repeatability of the KULR ONE platform revenue base, supported by a diversified customer base and ongoing engagements [39][40] Other Important Information - KULR has maintained its Bitcoin treasury of approximately 1,082 Bitcoins without selling any coins, despite recognizing a mark-to-market adjustment of $13.8 million for 2025 [6][28] - The company has ended a distribution relationship with a private Eskom company, resulting in a full write-off of approximately $6.9 million [8] Q&A Session Summary Question: Which markets are seeing the most momentum today? - The KULR ONE Air platform for autonomous systems shows the clearest production momentum, with over 20 active customer development agreements and a target of 10,000 battery packs per month by late 2026 [29] Question: Update on KULR's position in the AI data center backup power market? - KULR is developing its AI data center PBU product and expects revenue opportunities to materialize in 2027 [30][31] Question: Status in telecom and energy infrastructure? - KULR has commenced production for Caban Energy and is actively engaging with telecom operators for battery-as-a-service offerings [32][33] Question: Where is management most focused right now? - The primary focus for 2026 is on the KULR ONE Air platform, which shows the highest growth potential [35] Question: What are the biggest goals and milestones for 2026? - Key goals include ramping up production of KULR ONE Air products and securing contracts in telecom for battery-as-a-service [36][37] Question: How stable and repeatable is the KULR ONE platform revenue base? - The company is moving towards a more stable and repeatable product sales business model, supported by a broader customer engagement [39][40] Question: Potential role in space-based AI data centers? - While there may be opportunities, KULR does not see this as a focus for 2026 [41][42] Question: Revenue contributions from recent partnerships? - Caban and Hylio are expected to contribute to revenue in 2026, while AI data center business is anticipated for 2027 [43] Question: Alignment with companies planning to increase output? - KULR is focused on the KULR ONE Air platform and has set up an automated production line for 2026 [44][45]

Financial Data and Key Metrics Changes - For the full year 2025, total revenue was $0.6 million, down from $3.9 million in 2024, primarily due to lower grant revenue [18] - Product revenue for 2025 was $0.4 million, compared to $0.8 million in 2024, reflecting limited commercial activity [18] - Total operating expenses increased to $50.6 million in 2025 from $43.0 million in 2024, driven by a non-cash impairment charge of approximately $18.9 million [18] - Net loss for 2025 was $46.9 million, or a loss of $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share in 2024 [20] - Adjusted EBITDA was a loss of $28.0 million for 2025, compared to a loss of $33.5 million in 2024 [21] Business Line Data and Key Metrics Changes - Research and development expenses were $19.1 million in 2025, down from $21.0 million in 2024, reflecting disciplined investment in the Kodiak PCR platform [19] - Sales and marketing expenses decreased to $2.4 million in 2025 from $4.5 million in 2024, primarily due to lower personnel and consulting expenses [19] - General and administrative expenses were $9.1 million in 2025, down from $16.2 million in 2024, driven by lower legal and consulting expenses [19] Market Data and Key Metrics Changes - CoSara has expanded its commercial and distribution territory across South Asia, including Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the addressable market to approximately $13 billion [9] - The global TB diagnostics market is expected to grow significantly, with the company well-positioned to participate in that growth [15] Company Strategy and Development Direction - The company is focused on four primary growth pillars: advancing the clinical pipeline, expanding CoSara in India, executing the CoMira joint venture in Saudi Arabia, and enhancing AI-driven capabilities [6] - CoSara is expected to stand on its own as a public entity, with a potential SPAC transaction being explored to support capital needs [9] - The CoMira joint venture aims to establish local manufacturing and distribution capabilities in Saudi Arabia, providing a competitive advantage [12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of advancing clinical programs and achieving regulatory milestones to position the business for future revenue growth [23] - The company remains focused on disciplined capital allocation and evaluating financing alternatives to support objectives [23] - Management expressed confidence in the upcoming clinical studies for TB diagnostics, aligning with WHO guidelines [10] Other Important Information - The company has received international patents covering key components of the Kodiak PCR platform, enhancing its competitive positioning [13] - The Kodiak Primer AI platform is being expanded to unify efforts across diagnostics, data analytics, and operational efficiency [16] Q&A Session Summary Question: Status of sample accrual for the three target panel and potential to add COVID back - Management clarified that the decision to drop COVID was due to its limited presence during the clinical trial, allowing for a more expedient submission to the FDA [25] - Adding COVID back would not require redesign and would depend on negotiations with the FDA regarding sample requirements [27] Question: Expansion into South Asia and its implications - Management indicated that the disease burden in South Asia is similar to India, and the expansion increases the total addressable market from $11 billion to $13 billion [32] Question: Sample requirements for the U.S. FDA study - Management stated that over 1,200 patients have been enrolled for the study, nearing conclusion and preparation for FDA submission [35] Question: Next steps for commercialization in India - Management expects quick progression of clinical trials for TB diagnostics in India, with commercialization anticipated by the third quarter of 2026 [38]

Financial Data and Key Metrics Changes - Venu's total assets grew to $370 million as of December 31, 2025, up $192 million or 108% from $178 million at December 31, 2024 [22] - Property and equipment increased to $305 million as of December 31, 2025, up 123% from $137 million at December 31, 2024 [23] - Total revenue was $17 million for the full year ended December 31, 2025, compared to $17.8 million for the full year ended December 31, 2024 [24] Business Line Data and Key Metrics Changes - Luxe FireSuite and Aikman Club sales reached $126 million for the full year ended December 31, 2025, representing a 62% increase over the $77 million generated in fiscal year 2024 [24] - The triple-net model launched mid-year 2025 accounted for approximately 25% of total fire suite sales for the year [24] Market Data and Key Metrics Changes - Amphitheater revenue grew 94% year-over-year due to a full season in 2025 compared to a partial season in 2024 [10] - Demand from artists and promoters is at a level not seen before, with Ford Amphitheatre named to Billboard's 2026 Top Music Venues list [10] Company Strategy and Development Direction - The company is focused on building partnerships with world-class operators and expanding its venue portfolio, targeting a total of 40 potential locations [16][17] - A nationwide sales campaign is set to launch on April 15, aimed at moving hundreds of millions of dollars in inventory [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, emphasizing the strength of the balance sheet and the value of the assets [25] - The company is actively addressing operational challenges and refining its focus on high-potential venues [13] Other Important Information - Venu completed a $14 million sale-leaseback of its Colorado Springs parking property in Q4 2025, generating a development profit of $6.6 million [24] - The company has formed partnerships with major brands like PepsiCo and Aramark, enhancing its operational capabilities [17][18] Q&A Session Summary Question: Strategy to attract more institutional investors - Management acknowledged frustration with the current stock valuation and outlined plans to engage institutional investors through roadshows and a new IR strategy [28][30] Question: Future expansion plans and targeted markets - The company is actively negotiating in 13 markets and has formal RFPs out to 17 markets, focusing on strategic locations in Colorado and Texas [36][37] Question: Clarification on the $1.24 billion appraisal versus balance sheet assets - Management explained the disconnect arises from municipality-contributed real estate being recorded at zero cost basis on the balance sheet, while appraisals reflect market value [40][44] Question: Outlook for event supply and bookings - Management indicated a strong demand for amphitheater shows in 2026, with bookings activity nearly double compared to the previous year [48][50]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $9.7 million, up from $6 million in Q4 2024, with a total of 112 vehicles delivered in 2025 compared to 46 in 2024 [25][26] - Full-year 2025 revenue was $21.2 million, compared to $7 million in 2024; on a pro forma basis, total revenue for 2025 would have been $34 million, up from $13.7 million in 2024 [28][29] - Net loss for Q4 2025 was $23.7 million, compared to $19.6 million in the same period last year [28] Business Line Data and Key Metrics Changes - The merger with Motiv Electric Trucks was completed in December 2025, and the combined company is now a leading North American medium-duty commercial vehicle OEM [4][5] - The company delivered 65 vehicles in Q4 2025, with follow-on orders from existing customers driving the increase [25][26] Market Data and Key Metrics Changes - The North American medium-duty truck market is approximately $23 billion annually, with a significant shift towards e-commerce logistics and shorter delivery routes [10][12] - Annual mileage for medium-duty vehicles increased from roughly 31,000 miles in 2020 to nearly 48,000 miles in 2025, indicating a growing demand for these vehicles [12] Company Strategy and Development Direction - The company aims to complete integration, expand its product portfolio, and strengthen its financial position post-merger [6][10] - A new product roadmap is being developed to commonize key components and introduce a proprietary Class 5-6 cab chassis [9][20] - The company targets a run rate of $20 million in annualized cost synergies from the merger by the end of 2026 [7][20] Management's Comments on Operating Environment and Future Outlook - Management believes that capturing approximately 1% of the annual medium-duty truck market, or about 2,500 vehicles per year, is achievable and would lead to cash flow breakeven by the end of 2028 [17][18] - The company is focused on driving down costs to achieve pricing comparable to internal combustion engine trucks, leveraging merger synergies and economies of scale [19][20] Other Important Information - The company has a stronger balance sheet post-merger, with $12.9 million in cash and cash equivalents as of December 31, 2025 [29][30] - The company is actively exploring financing alternatives to support growth and strengthen its balance sheet [31] Q&A Session Summary Question: What were the one-time expenses related to the merger in Q4? - The company recognized over $4 million in one-time fees and costs associated with the merger, with expectations to exit 2026 at a $20 million run rate in synergies [36][39] Question: Will the company reach positive gross margins by Q4 2026? - Management indicated that it is unlikely to reach positive gross margins by Q4 2026, as it will take time to scale production [41] Question: What is the outlook for the step van market and feedback on the new lower-cost model? - Preliminary feedback on the new lower-cost models has been positive, with plans to mix the new vehicle with existing models for different duty cycles [45][46] Question: How will the Workhorse and Motiv products differ going forward? - The company will phase out the former Class 5-6 chassis from Motiv and ramp up production of new Class 5-6 cab chassis [58] Question: What are the plans to reduce the bill of materials during 2026? - The company aims to commonize components across its product lines to reduce the bill of materials and achieve competitive pricing with ICE trucks [60][62]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $2.8 million, a 116% increase from $1.3 million in Q4 2024 [16] - Gross profit for Q4 2025 was $2.3 million, up 148% from $0.9 million in Q4 2024, with gross margin expanding from 71.3% to 81.9% [16][5] - Full year 2025 revenue increased to $12.2 million, a 169% rise from $4.5 million in 2024, with gross profit increasing by 221% to $10 million [18][19] - Net loss for 2025 decreased by 29% to $22.5 million compared to $31.5 million in 2024 [19] Business Line Data and Key Metrics Changes - The company’s product suite includes various AI-powered marketing solutions, with significant contributions from subsidiaries like Vidello and OpenReel [4][5] - The acquisition of ConnectAndSell is expected to add approximately $15 million in annual revenue, potentially doubling the current annualized revenue to over $27 million [8][7] Market Data and Key Metrics Changes - The global martech market is rapidly expanding, driven by digital transformation and demand for personalized experiences [3] - The company serves over 150,000 customers across various sectors, including healthcare, financial services, and technology, indicating a broad market reach [13] Company Strategy and Development Direction - The company focuses on a strategy of building and acquiring products in key areas such as lead generation, engagement, tracking, and intelligence [4] - The acquisition strategy aims to strengthen the company’s position in the martech space and capitalize on industry consolidation [4][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in operational momentum and growth potential, emphasizing the importance of AI in enhancing product offerings and customer experiences [21][30] - The company is focused on maintaining operational discipline and efficiency while pursuing sustainable profitability [12][31] Other Important Information - The company secured an $11 million debt facility to support acquisitions and operations, reflecting strong investor confidence [6] - Recent leadership appointments are expected to enhance financial oversight and growth acceleration [6][13] Q&A Session Summary Question: What is the outlook for current M&A? - Management indicated ongoing interest in M&A opportunities, particularly the ConnectAndSell acquisition, which could significantly increase revenue [23][24] Question: How should we think about the combined company revenue and gross margin profile post-acquisition? - The combined revenue is expected to start at approximately $27 million, with gross margins anticipated to improve slightly upon consolidation [26] Question: What is the company's cash management strategy? - The company maintains a lean cash position while having access to an ATM and a substantial debt facility for operational support [31] Question: Is upselling gaining strength among the team? - Customer satisfaction remains high, with retention rates above 95%, indicating successful upselling efforts [36][41] Question: How is Superblocks being priced and packaged? - Superblocks is being considered both as a standalone product and as an integration into other products to enhance features [42]

Financial Data and Key Metrics Changes - Omeros reported a net income of $86.5 million or $1.22 per share for Q4 2025, a significant improvement from a net loss of $30.9 million or $0.47 per share in Q3 2025 [15][21] - The fourth quarter results included a net gain of $237.6 million from the sale of zaltenibart to Novo Nordisk [15][25] - Excluding a $136 million non-cash charge related to embedded derivatives, the non-GAAP adjusted net income was $222.5 million, translating to $3.14 per share [16][22] Business Line Data and Key Metrics Changes - The zaltenibart transaction with Novo Nordisk provided Omeros with an upfront cash payment of $240 million and potential milestone payments totaling up to $2.1 billion [5][6] - YARTEMLEA, the first approved treatment for TA-TMA, has begun commercial sales, with initial pricing set at approximately $36,000 per vial [10][12] Market Data and Key Metrics Changes - Omeros is focusing on the top 80 transplant centers in the U.S., which account for about 80% of annual stem cell transplants [10][11] - The company has achieved P&T committee approvals for YARTEMLEA at 50% of the top 10 U.S. transplant centers and is actively working to expand this coverage [12][34] Company Strategy and Development Direction - The company aims to achieve financial self-sustainability through the YARTEMLEA program in 2026 and expects to reach positive cash flow by 2027 [17][29] - Omeros is exploring additional indications for YARTEMLEA, including ARDS and solid organ transplant-related TMA, while also advancing its MASP-2 antibody and small molecule programs [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for YARTEMLEA, highlighting the urgency for treatment in transplant patients [35][49] - The company anticipates continued progress in P&T committee approvals and is optimistic about the reception of YARTEMLEA in the market [33][34] Other Important Information - Omeros has eliminated all indebtedness under its senior secured term loan and 2026 notes, leaving only $70.8 million in convertible notes due in 2029 [17][24] - The company is also advancing its TCAT platform for pathogen-targeting therapies, addressing the growing threat of multidrug-resistant organisms [18][19] Q&A Session Summary Question: Progress of formulary additions across transplant centers - Management is pleased with the speed of P&T committee approvals and expects continued progress throughout the year [33][34] Question: Real-world vial usage of YARTEMLEA - Initial usage shows a split of approximately 70% once weekly and 30% twice weekly, with expectations for a shift towards more frequent dosing as education efforts continue [37][38] Question: Financial sustainability and cash flow - The company aims for YARTEMLEA to be self-sustaining in 2026, with positive cash flow expected by 2027 [42][43] Question: Feedback from sales force on formulary allowance - The sales team reports positive responses from medical centers, with a strong recognition of the urgency for YARTEMLEA [45][47] Question: EMA decision and partnership discussions - The focus remains on achieving EMA approval for YARTEMLEA, with high interest noted at recent industry meetings [51][52] Question: Access to YARTEMLEA and patient starts - All requests for access to YARTEMLEA have been granted, with a mix of medical exceptions and formal formulary coverage [70][74]